Reagent kit sales surged 135% year-over-year in Q2 2024, driving recurring revenue growth, while cost reductions improved net loss. Recent equity and loan financing support US expansion amid strong market demand for microbiome diagnostics.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.